Core--Clinical trials
Core--Clinical trials
批准号:
6563968
负责人:
Roy S Herbst
金额:
$29.68万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-01-01 至 2002-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Description: (provided by applicant)
The primary goal of this research proposal is to develop techniques to assess
angiogenesis in patients using, (1) innovative immunohistochemical and
biochemical tests developed in our laboratories and, (2) non-invasive imaging.
To validate that these techniques can be applied to the clinical development
of antiangiogenic therapies, we will assess candidate biochemical assays and
noninvasive techniques through the ongoing and proposed preclinical and
clinical trials outlined in this proposal. The Clinical Trials Core will
manage the interface between the clinic, pharmacology laboratories (funded
separately U01 CA6246I PI: Abbruzzese), and tile research laboratories.
Each of the four Research Projects will utilize patient specimens or imaging
studies from one of four on-going or planned clinical trials. Four clinical
trials will be used to study and validate methods developed to assess the
antiangiogenic effects of novel agents developed in the laboratories
collaborating on this application. These include: (1) A phase II trial of the
anti-EGF antibody C225 + Gemcitabine in patients with pancreatic cancer, (2) A
phase I trial of the small molecule EGFR tyrosine kinase inhibitor PKII66, (3)
A phase I trial of human endostatin, (4) and the proposed phase I study of
tile small molecule receptor tyrosine kinase inhibitor SU6668, an agent that
inhibits the VEGF, basic FGF , and PDGF receptors. The Clinical Trials Core
will be responsible for organizing and distributing tile clinical specimens
obtained from these studies including tumor biopsies obtained for biological
studies, and will, therefore, interface closely with Core B (Biostatistics -Hess),
Core C (Histopathology Laboratory - Bucana), and Core E (Imaging
Resources - Scully). In addition, the Clinical Trials Core will organize the
imaging of patients on any clinical trails interfacing with Developmental
Projects 2 through 5.
In summary, the specific tasks of the Clinical Trials Core will be to (1)
develop high quality clinical trials designed to accomplish the translational
aims of the research projects and developmental projects, (2) coordinate
acquisition of tumor biopsy and other clinical specimens, (3) coordinate the
acquisition, distribution and analysis of diagnostic imaging studies, ( 4)
coordinate interactions with pharmacology to facilitate pharmacodynamic
analysis of data. (5) Provide data monitoring and coordinate audits.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Yale Cancer Center NCTN LAPS
-
批准号:10359158
-
项目类别:
-
资助金额:$48.49万
-
财政年份:2019
-
负责人:Roy S Herbst
-
依托单位:
Yale Cancer Center NCTN LAPS
-
批准号:10582614
-
项目类别:
-
资助金额:$87.91万
-
财政年份:2019
-
负责人:Roy S Herbst
-
依托单位:
Yale Cancer Center NCTN LAPS
-
批准号:10734497
-
项目类别:
-
资助金额:$12.0万
-
财政年份:2019
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:10203850
-
项目类别:
-
资助金额:$200.37万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer Developmental Research Program
-
批准号:10203857
-
项目类别:
-
资助金额:$8.96万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:9338869
-
项目类别:
-
资助金额:$71.51万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:9767058
-
项目类别:
-
资助金额:$213.48万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
-
批准号:8931829
-
项目类别:
-
资助金额:$218.5万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Core A: Administrative Core
-
批准号:10203851
-
项目类别:
-
资助金额:$15.48万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Administrative Core
-
批准号:8931832
-
项目类别:
-
资助金额:$86.07万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
MicroRNA-based interventions to prevent progression from lung preneoplasia to adenocarcinoma
-
批准号:9379210
-
项目类别:
-
资助金额:$20.76万
-
财政年份:2015
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8920514
-
项目类别:
-
资助金额:$55.45万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8707401
-
项目类别:
-
资助金额:$54.12万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8517039
-
项目类别:
-
资助金额:$52.79万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8332772
-
项目类别:
-
资助金额:$56.49万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
Personalizing NSCLC Therapy: Exploiting KRAS activated pathways
-
批准号:8186504
-
项目类别:
-
资助金额:$58.43万
-
财政年份:2011
-
负责人:Roy S Herbst
-
依托单位:
U10 Ful Member Application Affiliated with SWOG
-
批准号:7555078
-
项目类别:
-
资助金额:$21.59万
-
财政年份:2004
-
负责人:Roy S Herbst
-
依托单位:
U10 Full Member Application Affiliated with SWOG
-
批准号:7767468
-
项目类别:
-
资助金额:$32.57万
-
财政年份:2004
-
负责人:Roy S Herbst
-
依托单位:
Phase I trial of antiangiogenic agent SU6668 in Pt w solid tumors
-
批准号:6563965
-
项目类别:
-
资助金额:$29.68万
-
财政年份:2002
-
负责人:Roy S Herbst
-
依托单位:
Core--Clinical trials
-
批准号:6499818
-
项目类别:
-
资助金额:$29.68万
-
财政年份:2001
-
负责人:Roy S Herbst
-
依托单位:
海外基金